HanchorBio Inc.
SAN FRANCISCO, CA and TAIPEI, TAIWAN / ACCESSWIRE / December 1, 2023 / HanchorBio Inc., a global clinical-stage biotechnology company focusing on the discovery and development of innovative immuno-biomedicines to treat a wide variety of patients suffering from hard-to-treat solid tumors or hematological malignancies, today announced the acceptance of poster presentation at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) 2023 Annual Congress, taking place in Geneva, Switzerland and online from December 6-8, 2023.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Details of the presentation are as follows. The full abstracts will be made available on the ESMO website on Thursday, 30 November 2023 at 00:05 CET.
Title: An Engineered Ligand-Trap Biologic Targeting the CD47 Signaling Pathway for Cancer Treatment with Superb Efficacy and Safety Profiles
Presenter: Sean Juo, Ph.D., President and Chief Scientific Officer of HanchorBio
Location: Palexpo, Geneva, Switzerland
Presentation Number: #10951
Date and Time: Thursday, 7 December 2023 at 12:00-13:00 CET
Highlights from the Preclinical Data-
Key findings from the preclinical studies of HCB101 targeting the SIRPa- CD47 pathway include:
- HCB101 triggered strong phagocytic reactions against tumor cells but not red blood cells;
- HCB101 consistently showed excellent efficacy against hematological and solid malignancies in 14 human tumor xenograft models;
- Quantitative RNA transcriptional analysis indicated that HCB101 triggered drastic changes in gene expression inside the tumor compared to other competing molecules, suggesting a unique MOA underlying HCB101's superior efficacy;
- No adverse reaction was observed in cynomolgus monkey toxicology studies, indicating a good safety profile;
- HCB101 is currently being evaluated in a multi-regional, multi-center clinical study (NCT05892718) in the United States and Taiwan.
About HCB101
Discovered through structure-guided protein design which was further supplemented with relevant screening technologies, HCB101 is an engineered extracellular IgV domain of SIRPα fused to the Fc region of IgG4. HCB101 triggers potent phagocytic activity of macrophages by blocking the "do not eat" signal between macrophages and the tumor cells. Based on the extensive in-vitro and in-vivo preclinical data, HCB101 is potentially a much safer and more potent biologic than the anti-CD47 monoclonal antibodies and other SIRPα fusion proteins currently being investigated in clinical trials. Furthermore, quantitative RNA transcriptional analysis indicated that HCB101 triggered distinct gene expression profiles inside the tumor and in the tumor microenvironment compared to other relevant clinical candidates, suggesting that HCB101 might exhibit unique mechanisms of action. With IND clearance from the U.S. FDA and Taiwan FDA, HCB101 is currently being investigated in a multi-regional, multi-center, open-label, dose-finding clinical trial (NCT05892718) of adults with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma in the United States and Taiwan. Using HCB101 as the foundation, our multi-functional Fc-based designer biologics (FBDB™) platform pipeline includes other immune-modulating molecules targeting both adaptive and innate immunity to provide novel and efficacious treatments to patients suffering from difficult-to-treat cancers and other debilitating diseases.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio is a global clinical-stage biotechnology company focusing on immuno-oncology. The Company is led by an experienced team of pharmaceutical industry veterans with a proven track record of success in biologics discovery and global development to transcend current cancer therapies. Committed to reactivating the immune system to fight against diseases, the proprietary Fc-based designer biologics (FBDB™) platform enables unique biologics with diverse multi-targeting modalities to unleash both innate and adaptive immunity to overcome the current inadequacies of anti-PD1/L1 therapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By making breakthroughs in multi-functional innovative molecular configurations in R&D and improving the manufacturing process in CMC, HanchorBio develops transformative medicines to address unmet medical needs.
For more information, please visit HanchorBio or follow us on LinkedIn
Contact Information
Scott Liu
Founder, Chairman and CEO
scott_liu@hanchorbio.com
Yuehua Cong
Chief Business Officer
yuehua_cong@hanchorbio.com
SOURCE: HanchorBio Inc.
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/811807/hanchorbio-to-present-at-the-esmo-immuno-oncology-2023-annual-congress
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Formerra to Supply Foster Medical Compounds Across the Americas15.7.2025 16:45:00 CEST | Press release
Following GEON's acquisition of Foster, LLC, this new agreement expands Formerra's healthcare polymer portfolio with life-saving medical compounds. ROMEOVILLE, IL / ACCESS Newswire / July 15, 2025 / Formerra, a leader in performance materials distribution, today announced an agreement with GEON® Performance Solutions that designates Formerra as the preferred distributor of Foster®, LLC medical compounds in North America and South America. The agreement follows GEON's acquisition of Foster, LLC, and builds on Formerra's long-standing, global partnership with GEON for flexible and rigid PVC and filled polypropylene materials. "This expanded partnership equips our customers with a broader set of proven medical-grade solutions while leveraging Formerra's technical guidance and robust supply-chain capabilities," said Kelly Wessner, Vice President, Key Accounts, Formerra. "Foster's brand strength and GEON's investment momentum create powerful growth potential for these materials and our cust
FairWinds Migrates from .COM to .FAIRWINDS, Showcasing Leadership in Strategic Internet Addressing15.7.2025 16:00:00 CEST | Press release
WASHINGTON, DC / ACCESS Newswire / July 15, 2025 / FairWinds Partners, the world's leading domain name strategy consultancy, has completed the migration of its website from fairwindspartners.com to home.fairwinds. "This transition is more than a domain change. It reflects our belief in the future of .BRAND top-level domains," said FairWinds founder Josh Bourne. "Our move to .FAIRWINDS reinforces the strategic value that these top-level domains offer and our evolution from a pioneering domain name advisory firm to the trusted partner for global brands navigating the digital landscape via the address bar." Unlike second-level domains like google.com, top-level domains reside on the internet's root servers -- the foundation of the internet's naming system. .BRAND top-level domains are not publicly available and are used exclusively by the brand owner. ".BRAND top-level domains provide a powerful way to amplify, control, and secure a brand's digital presence while giving visitors visual pr
QorusDocs Reports 360% Increase in Customers Using AI to Manage Proposals, Acquires Shark Finesse to Build Unified AI-Powered Value and Proposal Platform15.7.2025 13:00:00 CEST | Press release
BELLEVUE, WA / ACCESS Newswire / July 15, 2025 / QorusDocs, an AI-powered proposal management software company that streamlines creation of pitches, proposals and request for proposal (RFP) responses, today announced that its customers' use of AI to manage proposals has grown 360% year over year, and that it has acquired Shark Finesse Ltd, a United Kingdom-based AI-powered customer value management software. "AI is completely transforming how business development teams win business, and QorusDocs is at the forefront," said Ray Meiring, CEO of QorusDocs. "The majority of our customers now rely on AI to manage proposals. We're at a pivotal moment, and with the acquisition of Shark Finesse, we're poised to deliver on companies' full revenue enablement journey, from proving value to winning the deal." QorusDocs Acquires Shark Finesse With Shark Finesse joining QorusDocs, the company's vision is to enable business development and proposal teams to prove value early in the revenue cycle, wit
AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease15.7.2025 09:50:00 CEST | Press release
Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin Lead indication is non-CF bronchiectasis; ATL-105 targets disease drivers through a broad multimodal mechanism of action VILNIUS, LT / ACCESS Newswire / July 15, 2025 / AATec Medical GmbH ("AATec"), a biotech company developing a multi-product platform for the treatment of respiratory diseases, and Northway Biotech ("Northway Biotech" or "NBT"), a global Contract Development and Manufacturing Organization (CDMO), today announced a partnership for manufacturing process development and analytical development of AATec's lead product candidate, ATL-105, a proprietary, inhaled therapy based on recombinant alpha-1 antitrypsin (AAT) for non-cystic fibrosis bronchiectasis (NCFB).AATec Medical and Northway Biotech Announce Partnership Under the agreement, Northway Biotech will leverage its expertise in biologics manufacturing to develop and scale the production process for ATL-
IXOPAY Surges Past 500 Certified Adapters, Solidifies Leadership in Enterprise-Grade Payment Orchestration15.7.2025 06:00:00 CEST | Press release
With 200 PSPs and 300 payment methods, IXOPAY is unlocking faster global expansion, improved approval rates, and full-stack control for enterprise merchants. LEHI, UT / ACCESS Newswire / July 15, 2025 / As global commerce accelerates, enterprise merchants are hitting a wall - their legacy payment stacks weren't built for the scale, complexity, or speed modern commerce demands. To stay competitive, merchants need infrastructure that adapts across markets, providers, and payment methods without costly rewrites or vendor lock-in. IXOPAY, a global leader in enterprise-grade payment orchestration, is addressing that challenge head-on with the announcement it has reached 500 certified adapters, connecting 200 payment service providers (PSPs) and 300 payment methods through a single, vendor-agnostic API. Payment orchestration is rapidly emerging as vital infrastructure for modern payments, and its effectiveness depends on the scale and breadth of the adapter ecosystem. IXOPAY's industry-leadi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom